HERCULES, CA--(Marketwired - Nov 7, 2013) - Bio-Rad Laboratories, Inc. (
Third-quarter reported revenues were $505.1 million, an increase of 1.3% compared to $498.7 million reported for the third quarter of 2012. These results include $5.5 million of sales resulting from the Company's acquisition of AbD Serotec in January 2013. On a currency-neutral basis, quarterly revenues increased 1.8% compared to the same period last year. Third-quarter gross margin was 56.3%, compared to 54.9% during the same quarter in 2012.
The Company recorded a net loss for the third quarter of ($7.1) million, or ($0.25) per share on a fully diluted basis versus net income of $42.6 million, or $1.49 per share reported for the same period last year. These results include interest expense of $15.6 million associated with our decision to redeem certain bonds in the third quarter of 2013 as well as the recording of an accrued expense of $20 million in connection with the Company's initial efforts to resolve the previously disclosed investigation of the Company in connection with the United States Foreign Corrupt Practices Act.
Year-to-date revenues were $1.53 billion, an increase of 2.3% compared to $1.50 billion reported in the first three quarters of 2012. Adjusting for the impact of currency, year-to-date revenue growth was 3.1%.
Year-to-date net income for the first three quarters of 2013 was $47.7 million, or $1.65 per share on a fully diluted basis compared to $122.2 million, or $4.27 per share reported during the same period in 2012.
In addition to the impact of the bond redemption and legal accrual mentioned above, the lower net income in the third quarter and year-to-date of 2013, when compared to the third quarter and year-to-date of 2012, was the result of higher SG&A expense, primarily due to employee expenses associated with acquisitions; expenses associated with the enterprise resource planning (ERP) implementation; as well as certain events that occurred during the first three quarters of 2012 that favorably impacted results in 2012 including reductions in the valuation of the contingent consideration associated with the QuantaLife acquisition of $8.5 million in the third quarter of 2012 and $16.0 million in the nine months ended September 30, 2012.
"As anticipated, third-quarter results continued the modest pace of growth set in the first half of the year," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "We continued to see a softness in some of our markets this quarter, which impacted our results. Although we expect more of the same for the rest of 2013, we remain focused on new products and investments in our future."
The Life Science segment net sales for the third quarter were $162.9 million, down 2.5% compared to the same period last year. On a currency-neutral basis, Life Science segment sales decreased by 1.2% compared to the third quarter of 2012. Third-quarter 2013 results reflected continued slowness in the research spending environment. Performance of the Life Science segment was positively impacted by sales of antibodies and reagents from the Company's acquisition of AbD Serotec, as well as sales of biochromatography and cell sorting instruments.
Reported net sales for the Clinical Diagnostics segment in the third quarter were $338.8 million, an increase of 3.2% compared to the third quarter in 2012 on both a reported and currency-neutral basis. During the quarter, the Clinical Diagnostics segment had growth across most product lines most notably from quality controls, diabetes, and autoimmune products. Strength in China and Latin America markets was offset by weakness of sales in Western Europe.
Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) November 7, 2013. Interested parties may access the call at 866-543-6403 (in the U.S.) or 617-213-8896 (international), access number 45118924.
A live webcast of the conference call may be accessed in the Investor Relations area of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 78604858, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for replay for up to a year and may be accessed in the Investor Relations area of www.bio-rad.com.
Bio-Rad Laboratories, Inc. (
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
|Bio-Rad Laboratories, Inc.|
|Condensed Consolidated Statements of Operations|
|(in thousands, except per share data)|
|Three Months Ended |
|Nine Months Ended |
|Cost of goods sold||220,850||224,927||674,330||654,784|
|Selling, general and administrative expense||202,238||160,134||583,486||492,913|
|Research and development expense||52,920||47,795||155,104||150,637|
|Income from operations||29,058||65,841||117,139||197,062|
|Foreign exchange losses, net||3,330||448||5,723||3,508|
|Other (income) expense, net||(667||)||(1,511||)||(10,711||)||(14,692||)|
|(Loss) income before income taxes||(5,216||)||55,003||67,875||170,748|
|Provision for income taxes||(1,883||)||(12,383||)||(20,200||)||(48,375||)|
|Net (loss) income including noncontrolling interests||(7,099||)||42,620||47,675||122,373|
|Net (income) loss attributable to noncontrolling interests||-||13||(21||)||(148||)|
|Net (loss) income attributable to Bio-Rad||$||(7,099||)||$||42,633||$||47,654||$||122,225|
|Basic (loss) earnings per share:|
|Net (loss) income per basic share attributable to Bio-Rad||$||(0.25||)||$||1.51||$||1.67||$||4.33|
|Weighted average common shares - basic||28,603||28,312||28,545||28,255|
|Diluted (loss) earnings per share:|
|Net (loss) income per diluted share attributable to Bio-Rad||$||(0.25||)||$||1.49||$||1.65||$||4.27|
|Weighted average common shares - diluted||28,603||28,645||28,870||28,609|
|Bio-Rad Laboratories, Inc.|
|Condensed Consolidated Balance Sheets|
|September 30, |
|December 31, |
|Cash and cash equivalents||$||291,793||$||463,388|
|Accounts receivable, net||383,471||398,739|
|Other current assets||205,749||161,750|
|Total current assets||1,674,543||1,936,682|
|Property, plant and equipment, net||425,076||416,938|
|Purchased intangibles, net||276,054||260,939|
|Accrued payroll and employee benefits||133,218||135,955|
|Notes payable and current maturities of long-term debt||1,705||1,750|
|Income and other taxes payable||32,424||34,779|
|Other current liabilities||163,639||169,049|
|Total current liabilities||462,885||472,400|
|Long-term debt, net of current maturities||435,541||732,414|
|Other long-term liabilities||257,742||223,149|
|Bio-Rad stockholders' equity||2,124,240||2,015,005|
|Total stockholders' equity||2,124,240||2,015,540|
|Total liabilities and stockholders' equity||$||3,280,408||$||3,443,503|
|Bio-Rad Laboratories, Inc.|
|Condensed Consolidated Statements of Cash Flows|
|Nine Months Ended |
|Cash flows from operating activities:|
|Cash received from customers||$||1,531,251||$||1,512,991|
|Cash paid to suppliers and employees||(1,341,006||)||(1,227,911||)|
|Income tax payments||(50,140||)||(77,411||)|
|Other operating activities||12,118||8,504|
|Net cash provided by operating activities||102,035||180,244|
|Cash flows from investing activities:|
|Payments for acquisitions and long-term investments||(68,510||)||(38,479||)|
|Other investing activities||105,425||(302,285||)|
|Net cash provided by (used in) investing activities||36,915||(340,764||)|
|Cash flows from financing activities:|
|Payments on long-term borrowings||(300,178||)||(496||)|
|Other financing activities||(15,287||)||9,569|
|Net cash (used in) provided by financing activities||(315,465||)||9,073|
|Effect of foreign exchange rate changes on cash||4,920||3,673|
|Net decrease in cash and cash equivalents||(171,595||)||(147,774||)|
|Cash and cash equivalents at beginning of period||463,388||574,231|
|Cash and cash equivalents at end of period||$||291,793||$||426,457|
|Reconciliation of net income including noncontrolling interests to net cash provided by operating activities:|
|Net income including noncontrolling interests||$||47,675||$||122,373|
|Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:|
|Depreciation and amortization||105,181||94,885|
|Changes in working capital||(59,545||)||(31,101||)|
|Net cash provided by operating activities||$||102,035||$||180,244|